In the Phase 1b dose expansion part of the study, heavily pretreated patients with metastatic melanoma were treated with IMA203. Data from the study showed a significant positive shift in median ...
On Thursday, Immatics N.V. (NASDAQ:IMTX) stock is trading lower after the company commenced an underwritten public offering ...
An experimental immunotherapy candidate targets toxic species of alpha-synuclein and was well tolerated in an ongoing, ...
Immatics (IMTX) has released an update. Immatics has reported promising updated Phase 1b clinical data for its ACTengine ...
Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial ...
A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.
Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...
The Union Cabinet on Wednesday (October 9, 2024) approved the development of the National Maritime Heritage Complex (NMHC) at ...
5hon MSN
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
The company’s recent Phase 1b trial of VK-0214, an oral therapy for the treatment of X-linked adrenoleukodystrophy (X-ALD), demonstrated significant reductions in very long chain fatty acids (VLCFAs), ...
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback